Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 43 | AXSANA: reevaluating the necessity of axillary dissection in breast cancer treatment

Rosa Di Micco • 3 Oct 2024
ESSO 43
Breast Cancer
AXSANA

Rosa Di Micco, MD, PhD, San Raffaele Scientific and Research Hospital in Milan, Italy, discusses the potential impact of the ongoing AXSANA trial (NCT04373655). The study may aims to reveal whether axillary dissection is still necessary, particularly if it’s only used as a staging procedure. Dr Micco suggests that with advancements in prognostic scoring systems, such as the CPS+EG score, surgeons might not need axillary surgery to gain staging information, potentially leading to a continued shift away from this procedure in breast cancer treatment. This interview took place at the ESSO 43 Congress in Antwerp, Belgium.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rosa Di Micco

The potential of AI in imaging for improved breast cancer detection and care
1:04
The potential of AI in imaging for improved breast cancer detection and care
Rosa Di Micco • 3 Oct 2024
CINDERELLA: AI app trial helps breast cancer pts visualize surgical outcomes for better satisfaction
1:05
CINDERELLA: AI app trial helps breast cancer pts visualize surgical outcomes for better satisfaction
Rosa Di Micco • 3 Oct 2024
Exploring cryoablation and robotic-assisted lumpectomy in breast cancer treatment
0:35
Exploring cryoablation and robotic-assisted lumpectomy in breast cancer treatment
Rosa Di Micco • 3 Oct 2024
Evolving role of axillary surgery in breast cancer after neoadjuvant chemotherapy
4:37
Evolving role of axillary surgery in breast cancer after neoadjuvant chemotherapy
Rosa Di Micco • 3 Oct 2024

Related Videos

How can genomic assays guide treatment in HR+/HER2- breast cancer?
1:26
How can genomic assays guide treatment in HR+/HER2- breast cancer?
Kevin Kalinsky • 25 Oct 2026
Disease control and patient-reported quality of life in the ASCENT-04 trial
0:56
Disease control and patient-reported quality of life in the ASCENT-04 trial
Kevin Kalinsky • 25 Oct 2026
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
1:02
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
Kevin Kalinsky • 25 Oct 2026
Treating triple negative early breast cancer after optimal neoadjuvant therapy
2:24
Treating triple negative early breast cancer after optimal neoadjuvant therapy
Joana Ribeiro • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals